Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Arcturus Therapeutics to related businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.
Earnings & Valuation
This table compares Arcturus Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Arcturus Therapeutics | $82.03 million | -$65.78 million | -3.05 |
| Arcturus Therapeutics Competitors | $717.36 million | $12.10 million | -14.88 |
Arcturus Therapeutics’ competitors have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Arcturus Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcturus Therapeutics | -285.92% | -46.79% | -36.50% |
| Arcturus Therapeutics Competitors | -12,285.98% | -196.04% | -30.61% |
Analyst Recommendations
This is a summary of current ratings and price targets for Arcturus Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcturus Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
| Arcturus Therapeutics Competitors | 9858 | 15137 | 45528 | 1590 | 2.54 |
Arcturus Therapeutics currently has a consensus target price of $24.50, indicating a potential upside of 160.92%. As a group, “Biotechnology” companies have a potential upside of 99.35%. Given Arcturus Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than its competitors.
Risk & Volatility
Arcturus Therapeutics has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Summary
Arcturus Therapeutics beats its competitors on 9 of the 12 factors compared.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA. The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
